Abiraterone acetate (with Prednisone)
Treatment for Prostate Cancer
Typical Dosage: 1000 mg once daily with Prednisone 5 mg twice daily
Effectiveness
80%
Safety Score
55%
Clinical Trials
194
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
1000 mg once daily with Prednisone 5 mg twice daily
Time to Effect
1-3 months (PSA response)
Treatment Duration
Continuous until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$28,000
Monitoring:$2,000
Side Effect Mgmt:$800
Total Annual:$30,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$31,514/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$47,385
Comparison vs ADT alone
Cost Difference
+$24,800/year
More expensive
QALY Difference
+2.50 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
3 active trials recruiting for Abiraterone acetate (with Prednisone) in Prostate Cancer
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
NCT03565835ACTIVE NOT RECRUITINGPHASE2
32 participants
INTERVENTIONAL
The Bronx, United States
Started: Jun 13, 2018
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
NCT02807805ACTIVE NOT RECRUITINGPHASE2
37 participants
INTERVENTIONAL
Sacramento, United States
Started: Oct 1, 2016
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT03833921RECRUITINGPHASE2
130 participants
INTERVENTIONAL
Houston, United States +2 more
Started: May 23, 2019
Completed Clinical Trials
15 completed trials for Abiraterone acetate (with Prednisone) in Prostate Cancer
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT00910754COMPLETEDPHASE1
33 participants
INTERVENTIONAL
Buffalo, United States +7 more
Started: May 1, 2009
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
NCT00544440COMPLETEDPHASE2
57 participants
INTERVENTIONAL
Houston, United States
Started: Oct 1, 2007
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
NCT01695135COMPLETEDPHASE3
214 participants
INTERVENTIONAL
Beijing, China +10 more
Started: Aug 9, 2012
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01715285COMPLETEDPHASE3
1.21K participants
INTERVENTIONAL
Buenos Aires, Argentina +207 more
Started: Feb 12, 2013
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
NCT04887506COMPLETEDPHASE3
107 participants
INTERVENTIONAL
Homewood, United States +41 more
Started: May 5, 2021
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
NCT00474383COMPLETEDPHASE2
47 participants
INTERVENTIONAL
San Francisco, United States +2 more
Started: Nov 1, 2006
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01017939COMPLETEDPHASE1
34 participants
INTERVENTIONAL
Beverly Hills, United States +5 more
Started: Jan 1, 2010
Abiraterone Acetate for Castrate Resistant Prostate Cancer
NCT01961843COMPLETEDNA
40 participants
INTERVENTIONAL
Boston, United States
Started: Jan 14, 2014
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
NCT00473746COMPLETEDPHASE1, PHASE2
66 participants
INTERVENTIONAL
San Francisco, United States +2 more
Started: Jun 1, 2006
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
NCT00485303COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Los Angeles, United States +13 more
Started: Jun 1, 2007
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
NCT01940276COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Birmingham, United States +13 more
Started: Oct 1, 2013
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
NCT02924766COMPLETEDPHASE1
34 participants
INTERVENTIONAL
West Hollywood, United States +5 more
Started: Oct 3, 2016
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
NCT01664728COMPLETEDPHASE1
54 participants
INTERVENTIONAL
Sutton, United Kingdom
Started: Apr 1, 2007
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
NCT01314118COMPLETEDPHASE2
131 participants
INTERVENTIONAL
Homewood, United States +44 more
Started: May 4, 2011
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
NCT00924469COMPLETEDPHASE2
58 participants
INTERVENTIONAL
Boston, United States +3 more
Started: Nov 1, 2009
Showing 20 of 195 total trials